Liposome bupivacaine for improvement in economic outcomes and opioid burden in GI surgery: IMPROVE Study pooled analysis.

16 – 19 Compared with a conventional opioid-based PCA regimen, the use of liposome bupivacaine was shown to significantly improve postsurgical outcomes in the individual studies, including reductions in opioid use, hospital length of stay (LOS), and hospitalization costs, although between-group differences did not reach statistical significance on every outcome measure in every study ( Table 1 ). 16 – 19 In this report, we present an analysis of pooled data across all of the IMPROVE studies.

also in 111,027 other papers

Of particular interest was the highly significant relative reduction of about 65% in the incidence of opioid-related AEs, which are known to be an important driver of increased LOS and cost in the postsurgical setting. 7 , 8 It is also interesting to note that the observed improvements in objective outcome measures (ie, reduced opioid consumption, LOS, hospitalization costs, and opioid-related AE incidence) did not appear to be counterbalanced by lower levels of patient-reported satisfaction with pain treatment at 30 days.

also in 132,142 other papers